The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients.
The Japanese Health Ministry panel commitee approve single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately ill COVID-19 patients.
The Japanese Health Ministry panel committee approvetheusageofthe single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately ill COVID-19 patients.
The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients.
